Revolution Medicines, Inc. (NASDAQ: RVMD), an EnterpriseWorks graduate, announced its United States patent on a matter of protection of its SHP2 inhibitors on March 18, 2020. The company specializes in clinical-stage oncology focusing on developing targeted therapies to inhibit frontier cancer targets. The company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the company is developing a broad portfolio of inhibitors composed of other key frontier oncology targets within the notorious RAS pathway and the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and SOS1 as well as RMC-5552, a development candidate within the company’s 4EBP1/mTORC1 program currently in IND-enabling studies.
“We have systematically built our SHP2 program intellectual property portfolio while advancing RMC-4630 in a multi-cohort Phase 1/2 clinical program. This patent reflects innovative work and provides important coverage for our SHP2 program compounds, including RMC-4630,” said Mark A. Goldsmith, M.D., Ph.D., president and chief executive officer of Revolution Medicines.
Revolution Medicines was founded at the University of Illinois Urbana-Champaign by researchers Mark Goldsmith, David Pompliano, and Martin Burke. Burke was a professor of chemistry at the University of Illinois Urbana-Champaign at the time of founding the company in 2015. In addition to his affiliations with the Beckman Institute, Carl R. Woese Institute for Genomic Biology, and the Biochemistry department, Burke is now the Associate Dean for Research and Professor at the Carle Illinois College of Medicine. He now serves as the scientific advisory board chairman for Revolution Medicines.
To view the full article from GlobeNewswire, click here.